These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28261513)

  • 41. Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.
    Verbiest A; Lambrechts D; Van Brussel T; Couchy G; Wozniak A; Méjean A; Lerut E; Oudard S; Verkarre V; Job S; de Reynies A; Machiels JP; Patard JJ; Zucman-Rossi J; Beuselinck B
    Clin Genitourin Cancer; 2018 Aug; 16(4):266-273. PubMed ID: 29503246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. VHL mutation analysis in patients with isolated central nervous system haemangioblastoma.
    Woodward ER; Wall K; Forsyth J; Macdonald F; Maher ER
    Brain; 2007 Mar; 130(Pt 3):836-42. PubMed ID: 17264095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Von Hippel-Lindau disease and aggressive GH-PRL pituitary adenoma in a young boy.
    Tudorancea A; François P; Trouillas J; Cottier JP; Girard JJ; Jan M; Gilbert-Dussardier B; Richard S; Lecomte P
    Ann Endocrinol (Paris); 2012 Feb; 73(1):37-42. PubMed ID: 22265326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
    Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
    Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phaeochromocytoma associated with a de novo VHL mutation as form fruste of von Hippel-Lindau disease.
    Frenzel S; Apel TW; Heidemann PH; Zerres K; Neumann HP; Dörr HG
    Eur J Pediatr; 2001 Jul; 160(7):421-4. PubMed ID: 11475579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease.
    Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE
    Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.
    Lolkema MP; Mans DA; Ulfman LH; Volpi S; Voest EE; Giles RH
    Eur J Hum Genet; 2008 Jan; 16(1):73-8. PubMed ID: 17912253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes.
    Griffiths DF; Williams GT; Williams ED
    Q J Med; 1987 Sep; 64(245):769-82. PubMed ID: 2897130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
    Prowse AH; Webster AR; Richards FM; Richard S; Olschwang S; Resche F; Affara NA; Maher ER
    Am J Hum Genet; 1997 Apr; 60(4):765-71. PubMed ID: 9106522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients.
    Cascón A; Escobar B; Montero-Conde C; Rodríguez-Antona C; Ruiz-Llorente S; Osorio A; Mercadillo F; Letón R; Campos JM; García-Sagredo JM; Benítez J; Malumbres M; Robledo M
    Hum Mutat; 2007 Jun; 28(6):613-21. PubMed ID: 17311301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis].
    Zhang N; Gong K; Guo HF; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1620-4. PubMed ID: 15569457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.
    Shenoy N; Pagliaro L
    Ann Oncol; 2016 Sep; 27(9):1685-95. PubMed ID: 27329246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A genetic register for von Hippel-Lindau disease.
    Maddock IR; Moran A; Maher ER; Teare MD; Norman A; Payne SJ; Whitehouse R; Dodd C; Lavin M; Hartley N; Super M; Evans DG
    J Med Genet; 1996 Feb; 33(2):120-7. PubMed ID: 8929948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.
    Martinez A; Fullwood P; Kondo K; Kishida T; Yao M; Maher ER; Latif F
    Mol Pathol; 2000 Jun; 53(3):137-44. PubMed ID: 10897333
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
    Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
    Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group.
    Richard S; Campello C; Taillandier L; Parker F; Resche F
    J Intern Med; 1998 Jun; 243(6):547-53. PubMed ID: 9681857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
    Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.